Lixte Biotechnology (LIXT) News Today → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free LIXT Stock Alerts $3.28 +0.06 (+1.86%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLixte Biotechnology (NASDAQ:LIXT) Trading 1.9% Higher americanbankingnews.com - April 25 at 1:48 AMMixed Shelf Filing Gives Micro Cap Delayed Boosttheglobeandmail.com - April 24 at 7:08 PMNEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE'S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESstockhouse.com - March 29 at 11:56 AMBiotech Steals The Show Following Pre-Clinical Data Announcementtheglobeandmail.com - March 27 at 3:34 PMLixte stock soars on preclinical data for lead drug LB-100msn.com - March 27 at 3:34 PMLixte Biotechnology Shares Rise 51% After Positive Data for LB-100 Cancer Treatmentmarketwatch.com - March 27 at 10:33 AMLIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatmentsglobenewswire.com - March 21 at 8:30 AMProfessor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Researchglobenewswire.com - February 27 at 8:30 AMLIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCIglobenewswire.com - February 26 at 8:30 AMLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborationsfinanznachrichten.de - November 14 at 7:09 AMLIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborationsfinance.yahoo.com - November 13 at 8:56 AMLixte Biotechnology Holdings Inc LIXTmorningstar.com - November 9 at 6:00 PMLIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaborationfinance.yahoo.com - October 16 at 1:29 PMLIXTE Appoints Bas van der Baan as President and Chief Executive Officerfinance.yahoo.com - September 26 at 9:39 AMLixte Biotechnology Holdings Inc. Wtwsj.com - August 27 at 9:14 AMLIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rulesfinance.yahoo.com - July 20 at 5:48 PMWhy Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com - July 18 at 6:38 PMLIXTE Biotechnology falls after company launches $3.5M registered direct offering of sharesmsn.com - July 18 at 1:38 PMLixte Bio Shares Tumble 31% After Pricing $3.5M Stock Offeringmarketwatch.com - July 18 at 1:38 PMLIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rulesfinance.yahoo.com - July 18 at 8:37 AMLixte Biotechnology Shares Rise 25% on LB-100 Cancer Treatment Researchmarketwatch.com - July 17 at 2:53 PMWhat's Going On With Lixte Biotechnology (LIXT) Stock?msn.com - July 17 at 2:53 PMmarketbeat.com - July 17 at 10:52 AMmarketbeat.com - July 17 at 10:15 AMmarketbeat.com - July 17 at 10:10 AMmarketbeat.com - July 17 at 9:58 AMPreclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapyfinance.yahoo.com - July 17 at 9:53 AMLIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirementsfinance.yahoo.com - June 23 at 1:08 PMLIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomasfinance.yahoo.com - June 7 at 3:56 PMOwning 53% in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) means that insiders are heavily invested in the company's futurefinance.yahoo.com - June 5 at 1:04 PMLIXTE Biotechnology Holdings announces reverse stock split to obtain minimum price compliancemsn.com - June 2 at 6:37 PMLixte Biotech Shares Down 8% After Company Announces Reverse Stock Splitmarketwatch.com - June 2 at 6:37 PMLIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023finance.yahoo.com - June 2 at 1:37 PMRecently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapyfinance.yahoo.com - May 30 at 1:10 PM8-K: LIXTE BIOTECHNOLOGY HOLDINGS, INC.marketwatch.com - May 12 at 12:24 AMGlobal Neurometabolic Disorders Market Share 2023-2030 with On-going Demand Statusmarketwatch.com - April 28 at 8:40 AMLIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcomafinance.yahoo.com - April 24 at 10:22 AMLIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancerfinance.yahoo.com - April 4 at 12:17 PMGaucher Disease Drugs Market Top Players By 2031marketwatch.com - March 24 at 8:24 AMProtein Phosphatase 2A Market Top Players and Forecast till 2028marketwatch.com - March 21 at 8:45 AMGaucher Disease Drugs Market Massive Growth Strikes Due To Technological Innovation During 2023-2028marketwatch.com - February 21 at 10:48 AMLIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCHfinance.yahoo.com - February 14 at 5:49 PMLixte Biotechnology Holdings, Inc. (LIXTW)finance.yahoo.com - February 13 at 11:13 AMIs Lixte Biotechnology Holdings (NASDAQ:LIXT) In A Good Position To Invest In Growth?finance.yahoo.com - February 8 at 8:57 AMLIXTE Biotechnology Stock Jumps As Lead Program Shows Cancer Killing Activity In Animal Modelsfinance.yahoo.com - February 7 at 7:37 PMLIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELSfinance.yahoo.com - February 7 at 2:36 PMmarketbeat.com - February 7 at 12:30 PMmarketbeat.com - February 7 at 12:18 PMGlobal Neurometabolic Disorders Market Size Growth Rate Analysis 2023 by Market Overview, Segments, Regions, Market Share and Forecast to 2028marketwatch.com - January 26 at 1:26 AMLIXT Lixte Biotechnology Holdings, Inc.seekingalpha.com - January 25 at 3:25 PM Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Will this $2 AI stock double overnight? (Ad)It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share! Click here to learn more >>> LIXT Media Mentions By Week LIXT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIXT News Sentiment▼0.090.44▲Average Medical News Sentiment LIXT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIXT Articles This Week▼20▲LIXT Articles Average Week Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CLVR News PULM News ASLN News KTTA News TFFP News CANF News EFTR News CMMB News CYCN News TRVN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIXT) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersNew Trump BombshellThe Freeport SocietyMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
